Marginal Zone Lymphoma
📧 Sign up to get email alerts when something new happens for Marginal Zone Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-05-06Clinical Trial Update: ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies [Phase 1, Phase 2]
Phase 1/2 trial of acalabrutinib (ACP-196) in combination with pembrolizumab in hematologic malignancies has completed with results posted i…
-
CLINICAL_TRIALS trial_result · 2022-03-03Clinical Trial Update: Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma [Phase 2]
Phase 2 study of zanubrutinib in marginal zone lymphoma has completed and results have been posted.
-
CLINICAL_TRIALS trial_result · 2022-02-10Clinical Trial Update: A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) [Phase 2]
A Phase 2 study evaluating INCB050465 in relapsed or refractory marginal zone lymphoma has completed, and results were posted on February 10…
-
CLINICAL_TRIALS trial_result · 2021-10-28Clinical Trial Update: BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) [Phase 2]
Phase 2 study of zanubrutinib (BGB-3111) in Chinese participants with Diffuse Large B-Cell Lymphoma (non-GCB) and indolent lymphomas (Follic…
-
FDA approval · 2021-10-14FDA Approved: LENALIDOMIDE — Original Application (Dr. Reddy's Laboratories Inc.)
The FDA approved Dr. Reddy's Laboratories' original application for lenalidomide (generic), authorizing a generic version of the cancer drug…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-09-29Clinical Trial Update: Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating lenalidomide in combination with rituximab for various stage III/IV indolent non-Hodgkin lymphoma subtypes; study c…
-
CLINICAL_TRIALS trial_result · 2021-09-14Clinical Trial Update: A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL) [Phase 1]
Phase 1 trial of TAK-659 as a single agent in adult East Asian participants with various non-Hodgkin lymphoma subtypes was terminated.
-
FDA approval · 2021-08-31FDA Approved: REVLIMID — Supplemental Application (Celgene Corporation)
The FDA approved a supplemental application for REVLIMID (lenalidomide) submitted by Celgene Corporation. The action expands or updates the …
-
CLINICAL_TRIALS trial_result · 2021-04-19Clinical Trial Update: Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients [Phase 1]
Phase 1/open-label pharmacokinetic study assessing interactions between tazemetostat and CYP enzymes and gastric pH in patients with B-cell …
-
CLINICAL_TRIALS trial_result · 2021-03-19Clinical Trial Update: Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL) [Phase 1]
Phase 1 trial in Japanese participants assessing safety, tolerability, and pharmacokinetics of idelalisib in relapsed or refractory indolent…
-
CLINICAL_TRIALS withdrawal · 2021-03-17Clinical Trial Update: A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) [Phase 3]
Phase 3 trial BRAVURA evaluating duvelisib with rituximab and bendamustine versus placebo in indolent non-Hodgkin lymphoma was withdrawn.
-
CLINICAL_TRIALS trial_result · 2021-01-28Clinical Trial Update: Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma [Phase 2]
Phase 2 clinical trial assessing SHC014748M for relapsed or refractory follicular lymphoma and marginal zone lymphoma.
-
FDA approval · 2020-04-21FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
FDA approved a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC.
-
CLINICAL_TRIALS trial_result · 2020-01-18Clinical Trial Update: Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma [Phase 2]
Phase 2 trial evaluating carfilzomib with or without rituximab in Waldenström macroglobulinemia or marginal zone lymphoma; study terminated …
-
CLINICAL_TRIALS trial_result · 2019-10-11Clinical Trial Update: Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer [Phase 2]
Phase 2 clinical trial update on donor umbilical cord blood transplant for hematologic cancers; status completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-08-13Clinical Trial Update: Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) [Phase 3]
Phase 3 trial update for rituximab plus lenalidomide in relapsed/refractory indolent non-Hodgkin lymphoma (follicular lymphoma and marginal …
-
CLINICAL_TRIALS trial_result · 2018-08-23Clinical Trial Update: Lenalidomide and R-CHOP in B-cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial updating the combination of lenalidomide with R-CHOP in various B-cell lymphomas; study completed.
-
CLINICAL_TRIALS trial_result · 2018-04-30Clinical Trial Update: Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients [Phase 2]
Phase 2 trial evaluating a three-drug regimen (Tacrolimus, Bortezomib, and Thymoglobulin) to prevent low-toxicity graft-versus-host disease …
-
CLINICAL_TRIALS trial_result · 2018-03-06Clinical Trial Update: Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating vorinostat in multiple low-grade non-Hodgkin lymphomas, including MALT lymphoma, nodal marginal zone lymphoma, foll…
-
FDA approval · 2018-02-06FDA Approved: ZYDELIG — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for ZYDELIG (idelalisib) filed by Gilead Sciences, Inc.
-
CLINICAL_TRIALS trial_result · 2017-11-17Clinical Trial Update: Low-Dose Radiation Therapy in Treating Patients With Follicular or Marginal Zone Non-Hodgkin's Lymphoma [Phase 3]
Phase 3 trial evaluating low-dose radiation therapy for follicular lymphoma and marginal zone lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2017-10-09Clinical Trial Update: Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma [Phase 2]
Phase 2 clinical trial evaluating the combination of pegfilgrastim and rituximab in patients with untreated, relapsed, or refractory follicu…
-
CLINICAL_TRIALS trial_result · 2017-09-29Clinical Trial Update: A Phase I/II Study of Intratumoral Injection of SD-101 [Phase 1, Phase 2]
Phase I/II trial investigating intratumoral SD-101 for various B-cell lymphomas; study completed with results posted in 2017.
-
CLINICAL_TRIALS research · 2017-08-29Clinical Trial Update: Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0
This clinical trial update reports on blood immunophenotyping techniques to aid staging of indolent B-cell lymphomas, including Follicular L…
-
CLINICAL_TRIALS trial_result · 2017-07-17Clinical Trial Update: First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. [Phase 3]
A Phase 3 trial comparing first-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphomas with maintenance therapy; the s…